Kolexia
Berriolo-Riedinger Alina Médecine nucléaire
Berriolo-Riedinger Alina
Médecine nucléaire
Centre Georges-François Leclerc
Dijon, France
107 Activités
66 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Lymphomes Tumeurs du sein Maladie de Hodgkin Lymphome B Lymphome B diffus à grandes cellules Lymphome folliculaire Métastase tumorale Carcinome canalaire du sein Seconde tumeur primitive

Collaborateurs

Voir plus
Casasnovas Rene-Olivier
Casasnovas Rene-Olivier
Hôpital François Mitterrand, Dijon, France
Meignan Michel
Meignan Michel
Hôpital Henri Mondor, Créteil, France
Kanoun Salim
Kanoun Salim
Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
Haioun Corinne
Haioun Corinne
Hôpital Henri Mondor, Créteil, France

Industries

Voir plus
Celgene
1 collaboration(s)
Dernière en 2018
{{person.topindus2.name}}
{{person.topindus2.tot}} collaboration(s)
Dernière en {{person.topindus2.last}}
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
LyMa101: Phase II Study to Evaluate the Efficacy of Upfront Obinutuzumab in Mantle Cell Lymphoma Patients Treated by DHAP Followed by Autologous Transplantation Plus Obinutuzumab Maintenance Then MRD Driven Maintenance
Essai Clinique (The Lymphoma Academic Research Organisation)   13 mars 2024
Phase 2 LYSA study of prednisone, vinblastine, doxorubicin, bendamustine for untreated older Hodgkin lymphoma patients.
Blood   18 novembre 2023
High PDL1/PDL2 gene expression correlates with worse outcome in primary mediastinal large B-cell lymphoma.
Blood advances   20 octobre 2023
Validation of the ΔSUV for Interim PET Interpretation in Diffuse Large B-Cell Lymphoma on the Basis of the GAINED Clinical Trial.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine   21 septembre 2023
MOLECULAR CHARACTERIZATION CONTRIBUTES TO DIAGNOSIS AND PREDICTS OUTCOME IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMAS: A LYSA STUDY
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 ‐ 17 June, 2023   09 juin 2023
A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma.
Blood advances   09 décembre 2022
Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study.
Leukemia & lymphoma   17 août 2022
Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   06 janvier 2022
Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA.
Blood   07 décembre 2021
BV-ICE: Phase I/II Feasibility Study of Brentuximab Vedotin in Refractory / Relapsed Hodgkin Lymphoma Patients Who Are Treated by Chemotherapy (ICE) in Second Line and Eligible for Autologous Transplantation
Essai Clinique (Millennium Pharmaceuticals)   06 décembre 2021